Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J9IH
|
|||
| Former ID |
DIB004376
|
|||
| Drug Name |
PELITREXOL
|
|||
| Synonyms |
AG-2037; Pelitrexol < USAN; AG-2032 (racemate); AG-2038 ((6R)-isomer); N-[5-[2-[2-Amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6(S)-yl]ethyl]-4-methylthien-2-ylcarbonyl]-L-glutamic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H25N5O6S
|
|||
| Canonical SMILES |
CC1=C(SC(=C1)C(=O)NC(CCC(=O)O)C(=O)O)CCC2CC3=C(NC2)N=C(NC3=O)N
|
|||
| InChI |
1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1
|
|||
| InChIKey |
QXOPTIPQEVJERB-JQWIXIFHSA-N
|
|||
| CAS Number |
CAS 446022-33-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycinamide ribonucleotide formyltransferase (GART) | Target Info | Inhibitor | [2], [3] |
| BioCyc | Purine nucleotides de novo biosynthesis | |||
| 5-aminoimidazole ribonucleotide biosynthesis | ||||
| Tetrahydrofolate salvage from 5,10-methenyltetrahydrofolate | ||||
| KEGG Pathway | Purine metabolism | |||
| One carbon pool by folate | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | De novo purine biosynthesis | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | Purine ribonucleoside monophosphate biosynthesis | |||
| WikiPathways | One Carbon Metabolism | |||
| Metabolism of nucleotides | ||||
| Folate Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00078468) Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment. U.S. National Institutes of Health. | |||
| REF 2 | Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075. | |||
| REF 3 | Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.